Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Free tools
NEWWebinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Explore the core engineering challenges of developing reliable high-temperature sensors for continuous emissions monitoring (CEMS) in industrial stacks — from material degradation to signal drift.
Article | Report Explore the 2026 anti-reflective coating materials landscape for solar glass: key chemistries, deposition methods, IP activity, and innovation trends shaping the sector.
Article | Report TAR-200 (Inlexzo) is Janssen's osmotic intravesical gemcitabine device targeting MIBC and high-risk NMIBC. Explore the patent landscape and Phase III pivotal data.
Article | Report Inclisiran's ORION-4 Phase III outcomes trial, siRNA vs PCSK9 antibody LDL-C reductions, MACE data, and the evolving cardiovascular IP landscape.
Article | Report Map the 2026 long read epigenome sequencing landscape: SMRT, nanopore, multimodal assays, and emerging IP signals across oncology, diagnostics, and agriculture.
Article | Report How iptacopan (Fabhalta) is reshaping PNH treatment by targeting Factor B orally — and what it means for ravulizumab and pegcetacoplan. Data-driven analysis.
Article | Report Explore the 2026 landscape of high-temperature PEM fuel cell membrane materials: PBI systems, phosphoric acid doping, MEA design, and key innovation trends.
Article | Report Explore how concurrent and sequential engineering development models differ for complex mechatronic product programs — and which approach accelerates R&D outcomes.
Article | Report Explore the key engineering tradeoffs between active and passive thermal control strategies for small satellite and CubeSat thermal management design.
Article | Report Explore the key differences between qualitative and quantitative accelerated aging protocols for polymer-based medical device materials, from Arrhenius models to shelf-life validation.
Article | Report Avidity Biosciences' AOC platform targets DM1 and DMD with antibody-oligonucleotide conjugates. Explore AOC 1001, AOC 1044, and Phase III readiness signals.
Article | Report Explore the supercapacitor electrode materials landscape in 2026: patent trends, key materials, and innovation intelligence for R&D and IP teams.
Article | Report A 2026 patent and literature landscape of grid-scale gravity energy storage: key mechanisms, assignees, emerging directions, and strategic IP implications.
Article | Report Wave-powered autonomous vessel patents 2012–2024: gyroscopic converters, hybrid energy systems, and AI navigation reshape zero-emission ocean operations.
Article | Report Gedatolisib (PKI-587) NDA filing in PIK3CA wild-type HR+/HER2− breast cancer: VIKTORIA-1 trial results, PI3K/mTOR pathway biology, and Celcuity/Pfizer strategy.